Within the next five years, Frankel believes that the technology they are using will evolve even more, perhaps to include holographic 3D models of homes they hope to build for their clients. Getty Images

For Frankel Building Group, the evolution of technology in the real estate and construction world was the next logical step in creating a sustainable and viable company. By incorporating technology into its client-based custom design and build firm through the use of a personal app and 3D renderings, co-president and principal Scott Frankel said Frankel Building Group is years ahead of the rest of the competition.

Frankel, who runs the company alongside his brother Kevin, described it as "a responsibility to do better and to show more."

"Our company, when I got here, was politely a little bit in the stone ages," Scott Frankel tells InnovationMap. "In order to be a customer facing business, and in order to compete in the market, we have learned to be a very technology-forward business. I would say out of every custom builder in the country, we are probably the most technology-reliant builder out there. That's a good thing."

The building group, which was started by 30 years ago by Scott and Kevin's father Jim, uses technology in every aspect of its projects.

Five to 10 years ago, builders would have to import designs into AutoCAD, a software that allows builders, engineers and architects to see their drawings in 3D form. Those AutoCAD drawings would then be printed and given to the homebuyer.

At Frankel Building Group, clients are able to login to an online portal that allows them to see every communication between them and the Frankel team, as well as building plans, updates, and digital 3D renderings of their homes. Everything from estimates to the latest updates from their assigned project manager are available to homebuyers from their phone.

"Our clients want that access," Frankel said. "If they don't get that access, they are going to be left with more questions than answers."

Frankel believes that they are only doing what the clients expect from a custom homebuilder: increasing communication through every means possible to make sure the client is satisfied with what the builder is doing.

"My brother and I are not huge technology guys," Frankel said. "We didn't come from this as framers who became custom builders. We came from a family that built custom homes and (using technology) only makes logical sense because it's something that makes it better. It's kind of like when you're banking with Chase and they came out with online banking — it just makes it better."

Within the next five years, Frankel believes that the technology they are using will evolve even more, perhaps to include holographic 3D models of homes they hope to build for their clients.

But, for now, Frankel Building Group is focused on growing their business one day at a time.

"Our focus is people in Houston who want to design and build that home for them on their property," Frankel said. "We just want to make sure we're putting the best product out there."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."